Answers are grounded in this paper and cite their sources.
Rubedo Life Sciences has raised $40 million in a series A financing round coled by Khosla Ventures and Ahren Innovation Capital. The start-up will develop small molecules targeting aging cells that drive skin and fibrotic diseases, starting with chronic atopic dermatitis and chronic psoriasis. The medicines are designed to clear away senescent cells, "enabling the shift from a maladaptive environment into a proregenerative response," says CEO Marco Quarta.
No takes yet. Share an insight, caveat, or question.
Rowan Walrath (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: